Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Blood Test Detects ALS with 98% Accuracy

By LabMedica International staff writers
Posted on 17 Sep 2024

Amyotrophic lateral sclerosis (ALS) is presently diagnosed via a neurologist’s clinical examination, but differentiating it from other neurological conditions requires tracking symptom progression, which can be challenging. More...

Given that the average survival time for ALS is about three years, many patients experience significant deterioration before receiving a confirmed diagnosis. Misdiagnosis rates can be as high as 68%, which delays treatment and causes patients to be shuffled between specialists, leading to increased anxiety, unnecessary interventions, and higher healthcare costs. Now, a blood test for diagnosing ALS could be available in as little as two years.

Researchers at Brain Chemistry Labs (Jackson, WY, USA) have discovered an ALS-specific biomarker, an "ALS fingerprint," in the blood. This biomarker, made up of eight microRNAs (miRNAs), can be detected with a simple blood test. The team utilized next-generation sequencing and real-time PCR to analyze blood samples from individuals with ALS, Primary Lateral Sclerosis (PLS), Parkinson’s disease (PD), and healthy controls. Their findings, published in Brain Communications, show that the eight-microRNA ALS fingerprint can diagnose ALS with up to 98% accuracy and distinguish it from PLS and PD.

To ensure the reliability of the test, it was validated across four different patient groups, in two separate laboratories, using various technicians and collection methods. The ALS fingerprint consistently produced reliable results. Researchers believe that this blood test could aid neurologists in diagnosing ALS, complementing current clinical evaluations. A simple blood test for ALS could be a breakthrough, as it would speed up diagnosis, reduce patient anxiety, lower healthcare costs, and facilitate the development of new treatments. Given the high misdiagnosis rate, a negative result could also be incredibly useful. Brain Chemistry Labs aims to partner with a diagnostic company and make this test widely available to neurologists within the next 18 to 24 months.

“Faster diagnoses will allow for earlier treatment, which will improve patient outcomes,” said Sandra Banack, lead author of the study.

Related Links:
Brain Chemistry Labs


Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
Laboratory Software
ArtelWare
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.